Literature DB >> 16502214

Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis.

Antonie Giaever Beiske, Kjell-Morten Myhr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16502214     DOI： 10.1007/s00415-006-0898-0

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  10 in total

1.  Severe necrotising cutaneous lesions complicating treatment with interferon beta-1a.

Authors:  A J Radziwill; S Courvoisier
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

2.  Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis.

Authors:  F Drago; C Brusati; G Mancardi; A Murialdo; A Rebora
Journal:  Arch Dermatol       Date:  1999-10

3.  Localized lipoatrophy after prolonged treatment with copolymer 1.

Authors:  G L Mancardi; A Murialdo; F Drago; C Brusati; R Croce; M Inglese; S Ratto
Journal:  J Neurol       Date:  2000-03       Impact factor: 4.849

4.  Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis.

Authors:  L Hwang; I Orengo
Journal:  Cutis       Date:  2001-10

Review 5.  Multiple sclerosis.

Authors:  J H Noseworthy; C Lucchinetti; M Rodriguez; B G Weinshenker
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

6.  Interferon beta-1b injection site reactions and necroses.

Authors:  A R Gaines; F Varricchio
Journal:  Mult Scler       Date:  1998-04       Impact factor: 6.312

7.  Lipoatrophy induced by recombinant human insulin injection.

Authors:  S Murao; K Hirata; T Ishida; J Takahara
Journal:  Intern Med       Date:  1998-12       Impact factor: 1.271

8.  Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b.

Authors:  W A Sheremata; J R Taylor; G W Elgart
Journal:  N Engl J Med       Date:  1995-06-08       Impact factor: 91.245

9.  Skin necrosis following a recombinant interferon-beta-1b injection.

Authors:  Chih-Hsun Yang; Chien Hsun Chen; Heng-Leong Chan
Journal:  Chang Gung Med J       Date:  2002-11

10.  Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.

Authors:  Catherine M Edgar; Donald G Brunet; Paul Fenton; E Vee McBride; Peter Green
Journal:  Can J Neurol Sci       Date:  2004-02       Impact factor: 2.104
  10 in total
  3 in total

1.  Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis.

Authors:  S S O'Sullivan; E M Cronin; B J Sweeney; J F Bourke; J Fitzgibbon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06-16       Impact factor: 10.154

2.  A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMA.

Authors:  Sara Bedrose; Christie G Turin; Victor R Lavis; Sang T Kim; Sonali N Thosani
Journal:  AACE Clin Case Rep       Date:  2020-01-03

3.  Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing-remitting multiple sclerosis?

Authors:  Zsolt Mezei; Daniel Bereczki; Lilla Racz; Laszlo Csiba; Tünde Csepany
Journal:  Neuropsychiatr Dis Treat       Date:  2012-10-23       Impact factor: 2.570
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.